Financings in Brief: Hemasure
This article was originally published in The Gray Sheet
Executive Summary
Hemasure: Files registration statement with the Securities and Exchange Commission for a proposed $28 mil. offering of 2.5 mil. shares of common stock. Smith Barney and Volpe, Welty & Co are managing the offering. Proceeds are expected to be used for marketing and manufacturing of the Marlborough, Massachusetts-based firm's LeukoNet pre-storage leukoreduction filtration system, cleared by FDA in June ("The Gray Sheet" Jan. 9, In Brief). Hemasure says funds also are tabbed for "conducting preclinical and clinical trials of its SteriPath blood pathogen inactivation system," R&D and "regulatory approvals for other planned products," and for general corporate purposes and working capital...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.